Jin Seok Ahn

Professor

Samsung Medical Center
Country flagSouth Korea
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Supplementary Figure 8. Circulating tumor DNA analysis data from Case 1. A, Allelic configuration analysis by liquid biopsy confirmed cis relationship between EGFR T790M and C797S mutations; no trans clones were detected. B, Serial changes in allelic frequency of all mutations detected in blood.

Year:

2025

Supplementary Figure 6. Analysis of BBT-176 using in vivo models. A, Body weight changes in Ba/F3 EGFR 19Del/C797S, EGFR 19Del/T790M/C797S and patient-derived xenograft models. The patient-derived xenograft was derived from a patient with poorly-differentiated adenocarcinoma harboring an EGFR 19Del/T790M/C797S mutation. B, BBT-176 activity in a LU1235 EGFR 19Del patient-derived xenograft model. Abbreviations: PDX, patient-derived xenograft; PO, orally; QD, once daily.

Year:

2025

Supplementary Figure 10. Growth inhibition by BBT-176 with and without osimertinib in BBT-176-resistant clones of EGFR 19Del/C797S (A) and EGFR 19Del/T790M/C797S (B) mutants. C, IC50 values for BBT-176 with and without osimertinib in BBT-176-resistant clones. IC50 values in nM were measured 3 days later and cell growth was plotted relative to untreated control cells (mean ± SD). Abbreviation: BR(1/2), BBT-176-resistant (clone 1/2).

Year:

2025

Supplementary Figure 9. Circulating tumor DNA analysis data from Case 2. A, Allelic configuration of T790M (red), L792H (green) and C797S (blue). B, Serial changes in allelic frequency of mutations detected in blood. C, Concentration-response curves and IC50 values of BBT-176 for EGFR 19Del/T790M/L792H mutant kinase.

Year:

2025

Supplementary Figure 5. Growth inhibition by BBT-176 with and without cetuximab in BBT-176-resistant clones. IC50 values were measured 3 days later and cell growth was plotted relative to untreated control cells (mean ± SD). Abbreviation: BR(1/2), BBT-176-resistant (clone 1/2).

Year:

2025

Purpose: Resistance to third-generation EGFR inhibitors including osimertinib arises in part from the C797S mutation in EGFR . Currently, no targeted treatment option is available for these patients. We have developed a new EGFR tyrosine kinase inhibitor (TKI), BBT-176, targeting the C797S mutation. Patients and Methods: Recombinant EGFR proteins and Ba/F3 cell lines, patient-derived cells, and patient-derived xenografts expressing mutant EGFR s were used to test the inhibitory potency and the anticancer efficacy of BBT-176 both in vitro and in vivo . Patient case data are also available from an ongoing phase I clinical trial (NCT04820023). Results: The half maximal inhibitory concentration (IC 50 ) of BBT-176 against EGFR 19Del/C797S, EGFR 19Del/T790M/C797S, and EGFR L858R/C797S proteins were measured at 4.36, 1.79, and 5.35 nmol/L, respectively (vs. 304.39, 124.82, and 573.72 nmol/L, for osimertinib). IC 50 values of BBT–176 against Ba/F3 cells expressing EGFR 19Del/C797S, EGFR 19Del/T790M/C797S, EGFR L858R/C797S, and EGFR L858R/T790M/C797S were 42, 49, 183, and 202 nmol/L, respectively (vs. 869, 1,134, 2,799, and 2,685 nmol/L for osimertinib). N-ethyl-N-nitrosourea mutagenesis suggested that BBT-176 treatment does not introduce any secondary mutations in the EGFR gene but increases EGFR expression levels. Combined with the EGFR antibody cetuximab, BBT-176 effectively suppressed the growth of BBT-176–resistant clones. BBT-176 strongly inhibited the tumor growth, and in some conditions induced tumor regression in mouse models. In the clinical trial, two patients harboring EGFR 19Del/T790M/C797S in blood showed tumor shrinkage and radiologic improvements. Conclusions: BBT-176 is a fourth-generation EGFR inhibitor showing promising preclinical activity against NSCLC resistant to current EGFR TKI, with early clinical efficacy and safety.

Year:

2025

Supplementary Figure 9. Circulating tumor DNA analysis data from Case 2. A, Allelic configuration of T790M (red), L792H (green) and C797S (blue). B, Serial changes in allelic frequency of mutations detected in blood. C, Concentration-response curves and IC50 values of BBT-176 for EGFR 19Del/T790M/L792H mutant kinase.

Year:

2024

Supplementary Figure 8. Circulating tumor DNA analysis data from Case 1. A, Allelic configuration analysis by liquid biopsy confirmed cis relationship between EGFR T790M and C797S mutations; no trans clones were detected. B, Serial changes in allelic frequency of all mutations detected in blood.

Year:

2024

Supplementary Figure 6. Analysis of BBT-176 using in vivo models. A, Body weight changes in Ba/F3 EGFR 19Del/C797S, EGFR 19Del/T790M/C797S and patient-derived xenograft models. The patient-derived xenograft was derived from a patient with poorly-differentiated adenocarcinoma harboring an EGFR 19Del/T790M/C797S mutation. B, BBT-176 activity in a LU1235 EGFR 19Del patient-derived xenograft model. Abbreviations: PDX, patient-derived xenograft; PO, orally; QD, once daily.

Year:

2024

Purpose: Resistance to third-generation epidermal growth factor receptor (EGFR) inhibitors including osimertinib arises in part from the C797S mutation in EGFR . Currently, no targeted treatment option is available for these patients. We have developed a new EGFR tyrosine kinase inhibitor (TKI), BBT-176, targeting C797S mutation. Patients and Methods: Recombinant EGFR proteins and Ba/F3 cell lines, patient-derived cells and patient-derived xenografts expressing mutant EGFRs were used to test the inhibitory potency and the efficacy of BBT-176 both in vitro and in vivo . Patient cases are derived from an ongoing phase 1 clinical trial (NCT04820023). Results: The half maximal inhibitory concentration (IC 50 ) of BBT-176 against EGFR 19Del/C797S, EGFR 19Del/T790M/C797S, and EGFR L858R/C797S protein were measured at 4.36, 1.79 and 5.35 nM, respectively (vs. 304.39, 124.82, and 573.72 nM, for osimertinib). IC 50 values of BBT‑176 against Ba/F3 cells expressing EGFR 19Del/C797S, EGFR 19Del/T790M/C797S, EGFR L858R/C797S, and EGFR L858R/T790M/C797S were 42, 49, 183 and 202 nM, respectively (vs 869, 1134, 2799, and 2685 nM for osimertinib). N-Ethyl-N-nitrosourea (ENU) mutagenesis suggested that BBT-176 treatment does not introduce any secondary mutations in the EGFR gene but increases EGFR expression levels. Combined with the EGFR antibody cetuximab, BBT‑176 effectively suppressed the growth of BBT-176-resistant clones. BBT‑176 strongly inhibited the tumor growth, and in some conditions induced tumor regression in mouse models. In the clinical trial, two patients from harboring EGFR 19Del/T790M/C797S in blood showed tumor shrinkage and radiological improvements. Conclusions: BBT-176 is a fourth-generation EGFR inhibitor showing promising preclinical activity against NSCLC resistant to current EGFR TKIs.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (5)

Sun Min Lim

Yonsei University College of Medicine

SOUTH KOREA
View details

Taiguang Jin

Head of Discovery Biology

BrightPath Biotherapeutics

UNITED STATES
View details

Gwanghee Lee

-

SOUTH KOREA
View details

Dong-Wan Kim

Associate Professor

Seoul National University Hospital

SOUTH KOREA
View details

Tetsuya Mitsudomi

Professor

Kindai University

JAPAN
View details